Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674633 · ClinicalTrials.gov registry record · NA
Software Treatment for Actively Reducing Severity of ADHD
A NA study of Attention Deficit Disorder With Hyperactivity, sponsored by Akili Interactive Labs.
- Completed
- Registry status
- NA
- Development phase
- 348
- Enrollment target
- 20
- Study locations
NCT02674633: Completed NA study of Attention Deficit Disorder With Hyperactivity, sponsored by Akili Interactive Labs.
NCT02674633 is a NA study of Attention Deficit Disorder With Hyperactivity that has completed, run by Akili Interactive Labs. The registered enrollment target is 348 participants, roughly in line with the 338-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02674633, a NA study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Akili Interactive Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 348 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of videogame-like digital therapies on attentional functioning and symptoms in children diagnosed with ADHD.
Primary Outcome
TOVA API is a comparison of the subject's scores based on selected measures that persons with an independent diagnosis of ADHD frequently demonstrated. The API is calculated from variability, response time, and d' (D Prime) using the following formula: API = Response Time Z score (Half 1) + d' Z score (Half 2) + Variability Z score (Total) + 1.80 where Response Time is the average time it takes to respond correctly to a target, d' score is a response discriminability score reflecting the ratio
Conditions Studied
Interventions
- DEVICE AKL-T01
- DEVICE AKL-T09
Study Locations (20)
California
- Avida, Inc. - Newport Beach
- University of California Davis MIND Institute - Sacramento
- University of California, San Francisco - San Francisco
Florida
- Meridien Research - Bradenton
- Florida Clinical Research Center - Maitland
North Carolina
- Duke Child and Family Study Center - Durham
- The Neuropsychiatric Clinic at Carolina Partners - Raleigh
Texas
- FutureSearch Trials - Dallas
- Bayou City Research, Ltd - Houston
Washington
- Northwest Clinical Research Center - Bellevue
- Seattle Children's - Seattle
Alabama
- Harmonex Neuroscience Research - Dothan
Arizona
- Melmed Center - Scottsdale
Illinois
- Capstone Clinical Research - Libertyville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-08-31 |
| Phase | NA |
What the finished NCT02674633 record still lists
NCT02674633 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 338-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target.
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 2 interventions - of which AKL-T01 is the first listed.
NCT02674633 names 20 study sites across 14 states, led by California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02674633 about?
NCT02674633 is a clinical study titled "Software Treatment for Actively Reducing Severity of ADHD". The purpose of this study is to evaluate the effects of videogame-like digital therapies on attentional functioning and symptoms in children diagnosed with ADHD.
What is the current status of trial NCT02674633?
This trial is currently completed. It is a NA study. The enrollment target is 348 participants. The study started on 2016-05. Estimated completion is 2017-08-31.
What conditions does trial NCT02674633 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT02674633?
The interventions under investigation include: AKL-T01 (DEVICE), AKL-T09 (DEVICE).
Who is sponsoring clinical trial NCT02674633?
This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02674633 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02674633's enrollment target sits among peer trials
348 3rd of 20 higher than 18 of 20 other Attention Deficit Disorder With Hyperactivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Disorder With Hyperactivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
-
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults
COMPLETED · NA
-
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
COMPLETED · NA
-
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
COMPLETED · NA
-
Software Treatment for Actively Reducing Severity of ADHD - Follow Up
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia